FDA OKs First Treatment for Interstitial Lung Disease Associated with Systemic Sclerosis

Nintedanib (Ofev, Boehringer Ingelheim) is now the first therapy approved for patients with interstitial lung disease associated with systemic sclerosis.
— Read on www.specialtypharmacytimes.com/

Another soft gel dosage (SGC) form product.

Leave a Reply

Your email address will not be published. Required fields are marked *